For purposes of this Article 48, the following terms have the following meanings:
“Buprenorphine” means the drug buprenorphine including any official name, common or usual name, chemical name, or brand name used to describe buprenorphine prescribed for the treatment of Opioid Use Disorder.
“City” means the City and County of San Francisco.
“Controlled Substance” means those substances referred to in the Federal Controlled Substances Act, Chapter 13 (commencing with Section 801) of Title 21 of the United States Code and the California Uniformed Controlled Substances Act, Division 10 (commencing with Section 11000) of the California Health and Safety Code.
“Department” means the San Francisco Department of Public Health.
“Director” means the Director of the San Francisco Department of Public Health or the Director’s designee.
“FDA” means the United States Food and Drug Administration.
“Opioid Antagonist” means Naloxone nasal spray (such as NARCAN®) or any other formulation of naloxone hydrochloride or similar drug approved or authorized by the FDA for the treatment of an opioid overdose.
“Pharmacist” means an individual licensed by the California State Board of Pharmacy to engage in the practice of pharmacy.
“Retail Pharmacy” means a licensed pharmacy, as defined in subdivision (a) of Section 4037 of the California Business and Professions Code, that is located in the City and dispenses drugs for retail sale.